IGLVIVOR22-1

Across TCGA pan-cancer cohorts, IGLVIVOR22-1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated IGLVIVOR22-1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGLVIVOR22-1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLVIVOR22-1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCS show a favorable association.

LIHC, HNSC, and CHOL are the cancer types where IGLVIVOR22-1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	II,III,IV	0.245	0.483	<.001	64	view →
HNSC	DFS	Tertile	All	0.784	0.667	.005	63	view →
CHOL	DFS	Tertile	All	0.134	0.587	.003	58	view →
KIRC	DFS	Quartile	III,IV	0.298	0.509	.007	50	view →
UVM	DFS	Median	III,IV	0.268	0.707	.005	45	view →
UCS	OS	Median	IV	0.732	0.224	.018	36	view →
KIRP	DFS	Tertile	IV	0.762	0.044	.021	30	view →
ACC	OS	Tertile	II,III,IV	0.135	0.658	.010	27	view →
GBM	OS	Median	All	0.319	0.210	.002	21	view →
MESO	OS	Tertile	IV	0.077	0.592	.019	18	view →
LGG	OS	Tertile	All	0.850	0.693	.006	16	view →
LAML	DFS	Tertile	All	0.455	0.717	.019	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

IGLVIVOR22-1–LIHC (DFS)

Open the LIHC breakdown →